Research programme: protocell-based anticancer therapeutics - Cascadian Therapeutics

Drug Profile

Research programme: protocell-based anticancer therapeutics - Cascadian Therapeutics

Latest Information Update: 09 Jun 2016

Price : $50

At a glance

  • Originator Oncothyreon
  • Developer Cascadian Therapeutics
  • Class Antineoplastics; Drug conjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Jun 2016 Oncothyreon is now called Cascadian Therapeutics
  • 15 Dec 2015 Research programme: protocell based anticancer therapeutics - Oncothyreon is available for licensing as of 15 Dec 2015. www.oncothyreon.com
  • 08 Dec 2015 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top